Should You Hold Halozyme Therapeutics (HALO)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 50,000,000 | $43,220,000 | 0.98% | ||
| 2. | 33,209,000 | $30,925,818 | -31% | 0% | |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 646,168 | $23,882,370 | -77% | 0.04% |
| 4. | 21,200,000 | $19,736,670 | 0.5% | ||
| 5. | 15,500,000 | $14,434,103 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | Director | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | Director | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | Director | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | Officer | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | Officer | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.49 | 10,000 | 168,176 | 2024-04-17 | Filing | ||
| $38.35 | 10,000 | 168,176 | 2024-04-16 | Filing | ||
| $42.27 | 10,000 | 156,558 | 2024-03-13 | Filing | ||
| $41.64 | 10,000 | 156,558 | 2024-03-12 | Filing | ||
| $39.54 | 7,471 | 156,558 | 2024-02-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,630,963 | $688,600,393 | 0.01% | |
| 2. | 13,259,514 | $490,071,638 | 0.01% | |
| 3. | 6,689,058 | $247,227,584 | 0.38% | |
| 4. | 6,475,549 | $239,336,291 | 0.01% | |
| 5. | 3,709,599 | $142,948,381 | 3.22% |
News See All
5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 5 most undervalued biotech stocks to buy according to hedge funds.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript
Halozyme Therapeutics, Inc. reports earnings inline with expectations. Reported EPS is $0.82 EPS, expectations were $0.82. Halozyme Therapeutics, Inc.
Halozyme Therapeutics (HALO) Underperformed Despite Strong Outlook
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” fourth-quarter 2023 investor letter, a copy of which can be downloaded here.
Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript
Operator: Hello and welcome to the Halozyme Third Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.
12 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into.
Should You Remain Confident in Halozyme Therapeutics (HALO)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, my name is Chris and I'll be your conference operator today.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Billionaire Hedge Funds
